ArticleCureus2026
Impact of Storage Temperature on Prevalence of Adverse Events in Nasal Saline Sprays: Exploratory Analysis of Post-market Clinical Follow-Up Data.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Nasal saline sprays are widely used for nasal hygiene and symptomatic relief in upper respiratory conditions. While nasal saline sprays are generally safe and well tolerated, the impact of storage conditions (particularly temperature) on their safety has not been evaluated. This post hoc exploratory analysis of data from three Post-Market Clinical Follow-Up (PMCF) studies investigated the association of storage temperature and prevalence of user-reported adverse events (AEs) across four nasal sprays: Otrivin Sea Water (OSW), Otrivin Sea Water with Aloe Vera (OSWAV), Otrisal 0.74% NaCl Metered-Dose Spray (MDS), and Prorhinel (Haleon plc, Weybridge, UK). Methods The analysis included all subjects from the Modified Intention to Treat (mITT) population across three pooled PMCF studies that evaluated the percentage of subjects who stored the sprays at room temperature (RT) (20-22 °C (68-72 °F)), at temperatures above RT (> 20-22 °C (68-72 °F)), and below RT (4-20 °C (40-68 °F)) and reported AEs. Odds ratios were calculated to assess the impact of storage temperature on the prevalence of AEs. Results Storage outside the RT was associated with increased risk of AEs across nasal saline spray products. The odds of experiencing an AE were approximately 8.94 times higher for OSW, 4.48 times higher for OSWAV, and 4.32 times higher for Prorhinel when stored outside RT, compared with storage within RT. When combined, the Bag of Value (BoV) products (OSW + OSWAV + Prorhinel) showed an overall odds ratio of 4.85 for the occurrence of AEs. Notably, storage above RT was linked to the highest AEs risk, with odds ratios of 15.32 and 14.87 for OSW and OSWAV, respectively. However, no AEs were reported in subjects when Otrisal MDS was stored outside RT. Conclusion This analysis demonstrated a significant correlation between storage temperatures outside RT and increased rates of AEs. These findings reinforce the current guidance provided in the instructions for use of nasal sprays, supporting RT as the optimal in-use temperature to ensure product safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.